The Latin America, Middle East and Africa Wound Debridement Market should witness market growth of 8.9% CAGR during the forecast period (2022-2028).
Rising economies and demographics of many developed and developing nations have resulted in the state governments investing more in the advancement and sustainability of the healthcare industry in their nations. The continual rise and development of healthcare infrastructure and expenditure, improving reimbursement policies, and provision of state help have helped in the development of cost-effective wound debridement products.
Throughout the world, chronic wound prevalence is rising, primarily fuelled by increasing diabetic and aging populations as well as the rising incidences of disease and conditions like obesity. These factors, along with several other situations like radiation therapy’s late effects, further aggravate conditions that increase the chances of acquiring a chronic wound.
Additionally, it has been found that ordinary people with chronic wounds also suffer from three or four chronic conditions like cardiovascular diseases (CVD), peripheral arterial disease (PAD), and chronic obstructive pulmonary disorder (COPD). Furthermore, the growing awareness of people to lead a healthy life has shifted their focus to adopting a holistic approach to attain improved well-being and health.
High Body Mass Index (BMI) is considered to be the prominent cause of diabetes, primarily type 2. This is specifically true in the Latin American region's case. The high BMI of a larger proportion of population has subsequently increased the prevalence of diabetes and diabetes-associated mortality, which has been found to be among the highest in the world. Consequently, the high incidences of diabetes have become a significant threat to the economy, health systems, and population health in many nations of the region.
The Brazil market dominated the LAMEA Wound Debridement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $112.9 million by 2028. The Argentina market is experiencing a CAGR of 9.5% during (2022-2028). Additionally, The UAE market would display a CAGR of 8.7% during (2022-2028).
Based on Mode of Purchase, the market is segmented into Prescription, Over The Counter and Others. Based on Product, the market is segmented into Medical Gauzes, Gels, Surgical Devices, Ultrasonic Devices, Ointments & Creams and Others. Based on Method, the market is segmented into Surgical, Autolytic, Enzymatic, Mechanical and Others. Based on Wound Type, the market is segmented into Diabetic Foot Ulcers, Pressure Ulcers, Burn Wounds and Venous Leg Ulcers & Others. Based on End-use, the market is segmented into Hospitals, Homecare and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Coloplast Group, Medline Industries, Inc., Smith & Nephew PLC, Medtronic PLC, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.), Johnson & Johnson (Ethicon, Inc.), Baxter International, Inc., and Molnlycke Health Care AB.
Rising economies and demographics of many developed and developing nations have resulted in the state governments investing more in the advancement and sustainability of the healthcare industry in their nations. The continual rise and development of healthcare infrastructure and expenditure, improving reimbursement policies, and provision of state help have helped in the development of cost-effective wound debridement products.
Throughout the world, chronic wound prevalence is rising, primarily fuelled by increasing diabetic and aging populations as well as the rising incidences of disease and conditions like obesity. These factors, along with several other situations like radiation therapy’s late effects, further aggravate conditions that increase the chances of acquiring a chronic wound.
Additionally, it has been found that ordinary people with chronic wounds also suffer from three or four chronic conditions like cardiovascular diseases (CVD), peripheral arterial disease (PAD), and chronic obstructive pulmonary disorder (COPD). Furthermore, the growing awareness of people to lead a healthy life has shifted their focus to adopting a holistic approach to attain improved well-being and health.
High Body Mass Index (BMI) is considered to be the prominent cause of diabetes, primarily type 2. This is specifically true in the Latin American region's case. The high BMI of a larger proportion of population has subsequently increased the prevalence of diabetes and diabetes-associated mortality, which has been found to be among the highest in the world. Consequently, the high incidences of diabetes have become a significant threat to the economy, health systems, and population health in many nations of the region.
The Brazil market dominated the LAMEA Wound Debridement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $112.9 million by 2028. The Argentina market is experiencing a CAGR of 9.5% during (2022-2028). Additionally, The UAE market would display a CAGR of 8.7% during (2022-2028).
Based on Mode of Purchase, the market is segmented into Prescription, Over The Counter and Others. Based on Product, the market is segmented into Medical Gauzes, Gels, Surgical Devices, Ultrasonic Devices, Ointments & Creams and Others. Based on Method, the market is segmented into Surgical, Autolytic, Enzymatic, Mechanical and Others. Based on Wound Type, the market is segmented into Diabetic Foot Ulcers, Pressure Ulcers, Burn Wounds and Venous Leg Ulcers & Others. Based on End-use, the market is segmented into Hospitals, Homecare and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Coloplast Group, Medline Industries, Inc., Smith & Nephew PLC, Medtronic PLC, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.), Johnson & Johnson (Ethicon, Inc.), Baxter International, Inc., and Molnlycke Health Care AB.
Scope of the Study
By Mode of Purchase
- Prescription
- Over The Counter
- Others
By Product
- Medical Gauzes
- Gels
- Surgical Devices
- Ultrasonic Devices
- Ointments & Creams
- Others
By Method
- Surgical
- Autolytic
- Enzymatic
- Mechanical
- Others
By Wound Type
- Diabetic Foot Ulcers
- Pressure Ulcers
- Burn Wounds
- Venous Leg Ulcers & Others
By End-use
- Hospitals
- Homecare
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- 3M Company
- Coloplast Group
- Medline Industries, Inc.
- Smith & Nephew PLC
- Medtronic PLC
- ConvaTec Group PLC
- Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
- Johnson & Johnson (Ethicon, Inc.)
- Baxter International, Inc.
- Molnlycke Health Care AB
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Wound Debridement Market, by Purchase
1.4.2 LAMEA Wound Debridement Market, by Product
1.4.3 LAMEA Wound Debridement Market, by Method
1.4.4 LAMEA Wound Debridement Market, by Wound Type
1.4.5 LAMEA Wound Debridement Market, by End-use
1.4.6 LAMEA Wound Debridement Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. LAMEA Wound Debridement Market by Mode of Purchase
4.1 LAMEA Prescription Market by Country
4.2 LAMEA Over The Counter Market by Country
4.3 LAMEA Others Market by Country
Chapter 5. LAMEA Wound Debridement Market by Product
5.1 LAMEA Medical Gauzes Market by Country
5.2 LAMEA Gels Market by Country
5.3 LAMEA Surgical Devices Market by Country
5.4 LAMEA Ultrasonic Devices Market by Country
5.5 LAMEA Ointments & Creams Market by Country
5.6 LAMEA Others Market by Country
Chapter 6. LAMEA Wound Debridement Market by Method
6.1 LAMEA Surgical Market by Country
6.2 LAMEA Autolytic Market by Country
6.3 LAMEA Enzymatic Market by Country
6.4 LAMEA Mechanical Market by Country
6.5 LAMEA Others Market by Country
Chapter 7. LAMEA Wound Debridement Market by Wound Type
7.1 LAMEA Diabetic Foot Ulcers Market by Country
7.2 LAMEA Pressure Ulcers Market by Country
7.3 LAMEA Burn Wounds Market by Country
7.4 LAMEA Venous Leg Ulcers & Others Market by Country
Chapter 8. LAMEA Wound Debridement Market by End-use
8.1 LAMEA Hospitals Market by Country
8.2 LAMEA Homecare Market by Country
8.3 LAMEA Others Market by Country
Chapter 9. LAMEA Wound Debridement Market by Country
9.1 Brazil Wound Debridement Market
9.1.1 Brazil Wound Debridement Market by Mode of Purchase
9.1.2 Brazil Wound Debridement Market by Product
9.1.3 Brazil Wound Debridement Market by Method
9.1.4 Brazil Wound Debridement Market by Wound Type
9.1.5 Brazil Wound Debridement Market by End-use
9.2 Argentina Wound Debridement Market
9.2.1 Argentina Wound Debridement Market by Mode of Purchase
9.2.2 Argentina Wound Debridement Market by Product
9.2.3 Argentina Wound Debridement Market by Method
9.2.4 Argentina Wound Debridement Market by Wound Type
9.2.5 Argentina Wound Debridement Market by End-use
9.3 UAE Wound Debridement Market
9.3.1 UAE Wound Debridement Market by Mode of Purchase
9.3.2 UAE Wound Debridement Market by Product
9.3.3 UAE Wound Debridement Market by Method
9.3.4 UAE Wound Debridement Market by Wound Type
9.3.5 UAE Wound Debridement Market by End-use
9.4 Saudi Arabia Wound Debridement Market
9.4.1 Saudi Arabia Wound Debridement Market by Mode of Purchase
9.4.2 Saudi Arabia Wound Debridement Market by Product
9.4.3 Saudi Arabia Wound Debridement Market by Method
9.4.4 Saudi Arabia Wound Debridement Market by Wound Type
9.4.5 Saudi Arabia Wound Debridement Market by End-use
9.5 South Africa Wound Debridement Market
9.5.1 South Africa Wound Debridement Market by Mode of Purchase
9.5.2 South Africa Wound Debridement Market by Product
9.5.3 South Africa Wound Debridement Market by Method
9.5.4 South Africa Wound Debridement Market by Wound Type
9.5.5 South Africa Wound Debridement Market by End-use
9.6 Nigeria Wound Debridement Market
9.6.1 Nigeria Wound Debridement Market by Mode of Purchase
9.6.2 Nigeria Wound Debridement Market by Product
9.6.3 Nigeria Wound Debridement Market by Method
9.6.4 Nigeria Wound Debridement Market by Wound Type
9.6.5 Nigeria Wound Debridement Market by End-use
9.7 Rest of LAMEA Wound Debridement Market
9.7.1 Rest of LAMEA Wound Debridement Market by Mode of Purchase
9.7.2 Rest of LAMEA Wound Debridement Market by Product
9.7.3 Rest of LAMEA Wound Debridement Market by Method
9.7.4 Rest of LAMEA Wound Debridement Market by Wound Type
9.7.5 Rest of LAMEA Wound Debridement Market by End-use
Chapter 10. Company Profiles
10.1 Medtronic PLC
10.1.1 Company overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.1.6 SWOT Analysis
10.2 ConvaTec Group PLC
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Product Category and Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.2.5.2 Acquisitions and Mergers:
10.2.5.3 Product Launches and Expansions:
10.3 Coloplast Group
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental and Regional Analysis
10.3.4 Research & Development Expense
10.4 3M Company
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Acquisitions and Mergers:
10.5 Smith & Nephew PLC
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Geographical Expansions:
10.5.5.2 Acquisitions and Mergers:
10.6 Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.7 Baxter International, Inc.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental Analysis
10.7.4 Research & Development Expense
10.7.5 Recent strategies and developments:
10.7.5.1 Acquisition and Mergers:
10.8 Johnson & Johnson (Ethicon, Inc.)
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental &Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Acquisition and Mergers:
10.9 Medline Industries, Inc.
10.9.1 Company Overview
10.9.2 Recent strategies and developments:
10.9.2.1 Partnerships, Collaborations, and Agreements:
10.10. Molnlycke Health Care AB
10.10.1 Company Overview
10.10.2 Recent strategies and developments:
10.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- 3M Company
- Coloplast Group
- Medline Industries, Inc.
- Smith & Nephew PLC
- Medtronic PLC
- ConvaTec Group PLC
- Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
- Johnson & Johnson (Ethicon, Inc.)
- Baxter International, Inc.
- Molnlycke Health Care AB
Methodology
LOADING...
